124 related articles for article (PubMed ID: 11925905)
1. [Possible roles of TNF family cytokines in bone destruction of rheumatoid arthritis].
Udagawa N; Kotake S; Kamatani N; Takahashi N; Suda T
Ryumachi; 2002 Feb; 42(1):3-12. PubMed ID: 11925905
[No Abstract] [Full Text] [Related]
2. [Osteoclastic bone resorption in joint destruction of rheumatoid arthritis].
Kawaguchi H
Ryumachi; 2000 Feb; 40(1):32-8. PubMed ID: 10783664
[No Abstract] [Full Text] [Related]
3. [Role of osteoclasts in bone destruction in rheumatoid arthritis].
Suzuki Y
Nihon Rinsho Meneki Gakkai Kaishi; 2001 Jun; 24(3):87-97. PubMed ID: 16578961
[No Abstract] [Full Text] [Related]
4. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
Tanaka S; Nakamura K; Takahasi N; Suda T
Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
[TBL] [Abstract][Full Text] [Related]
5. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis.
Edwards JR; Sun SG; Locklin R; Shipman CM; Adamopoulos IE; Athanasou NA; Sabokbar A
Arthritis Rheum; 2006 May; 54(5):1451-62. PubMed ID: 16649193
[TBL] [Abstract][Full Text] [Related]
6. Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates.
Romas E
Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):1065-79. PubMed ID: 16301197
[TBL] [Abstract][Full Text] [Related]
7. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha.
Dai SM; Nishioka K; Yudoh K
Ann Rheum Dis; 2004 Nov; 63(11):1379-86. PubMed ID: 15479886
[TBL] [Abstract][Full Text] [Related]
8. Rheumatic diseases: the effects of inflammation on bone.
Walsh NC; Crotti TN; Goldring SR; Gravallese EM
Immunol Rev; 2005 Dec; 208():228-51. PubMed ID: 16313352
[TBL] [Abstract][Full Text] [Related]
9. [RANKL/RANK signaling in rheumatoid arthritis].
Omata Y; Tanaka S
Clin Calcium; 2011 Aug; 21(8):1175-80. PubMed ID: 21814022
[TBL] [Abstract][Full Text] [Related]
10. Interplay between interferon and other cytokine systems in bone metabolism.
Takayanagi H; Sato K; Takaoka A; Taniguchi T
Immunol Rev; 2005 Dec; 208():181-93. PubMed ID: 16313349
[TBL] [Abstract][Full Text] [Related]
11. [Merger of bone biology and immunology].
Suda T; Shima N; Higashio K
Tanpakushitsu Kakusan Koso; 2002 Oct; 47(13):1837-43. PubMed ID: 12385106
[No Abstract] [Full Text] [Related]
12. Arthritis -- a nightmare for bone.
Schett G
Wien Klin Wochenschr; 2006 Feb; 118(1-2):11-5. PubMed ID: 16489519
[No Abstract] [Full Text] [Related]
13. IFN-gamma-producing human T cells directly induce osteoclastogenesis from human monocytes via the expression of RANKL.
Kotake S; Nanke Y; Mogi M; Kawamoto M; Furuya T; Yago T; Kobashigawa T; Togari A; Kamatani N
Eur J Immunol; 2005 Nov; 35(11):3353-63. PubMed ID: 16220542
[TBL] [Abstract][Full Text] [Related]
14. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.
Anandarajah AP; Schwarz EM
J Cell Biochem; 2006 Feb; 97(2):226-32. PubMed ID: 16240334
[TBL] [Abstract][Full Text] [Related]
15. The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.
Yeung RS
J Rheumatol; 2004 May; 31(5):844-6. PubMed ID: 15124240
[No Abstract] [Full Text] [Related]
16. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.
Urushibara M; Takayanagi H; Koga T; Kim S; Isobe M; Morishita Y; Nakagawa T; Löeffler M; Kodama T; Kurosawa H; Taniguchi T
Arthritis Rheum; 2004 Mar; 50(3):794-804. PubMed ID: 15022321
[TBL] [Abstract][Full Text] [Related]
17. [Bone disease related to rheumatoid arthritis].
Tanaka S
Nihon Rinsho; 2006 Sep; 64(9):1712-7. PubMed ID: 16972685
[TBL] [Abstract][Full Text] [Related]
18. [Osteopontin in rheumatoid arthritis].
Saeki Y
Nihon Rinsho; 2005 Oct; 63 Suppl 10():627-31. PubMed ID: 16279713
[No Abstract] [Full Text] [Related]
19. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
[TBL] [Abstract][Full Text] [Related]
20. [Pathogenesis of bone involvement in patients with rheumatoid arthritis].
Lewicki M; Lewicka K; Goździk J; Kucharz EJ
Przegl Lek; 2002; 59(11):912-5. PubMed ID: 12715721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
